At the time, a former Teva chief executive, Jeremy Levin, described it as a great deal for Allergan. He and others believed that given the continuing decline in generic prices, Teva had vastly overpaid for the acquisition. Other critics have long said that pursuing market share in the generic-drug
Date: Dec 27, 2017
Category: Business
Source: Google
Teva Pharma (TEVA) CEO Resigns, Citi Says Covenant Impact Not A Concern
Citi analyst Liav Abraham comments on the impact saying (emphasis ours) "Following the sudden departure of Jeremy Levin as TEVAs CEO in late 2013, we commented on the potential challenges in the search for a CEO at TEVA. Todays situation is no different, given (i) the perceived challenges facing t
Date: Feb 07, 2017
Category: Business
Source: Google
Defying Patient Pressure, Anthem Says No to Sarepta's Duchenne Drug
That [Anthem decision] will have quite a substantial impact, says Jeremy Levin, the CEO of New York-based Ovid Therapeutics, which is developing drugs for rare brain disorders. Levin, who is also the former head of generics giant Teva Pharmaceutical Industries, is concerned about the ramifications
harmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Dr. Jeremy Levin has been appointed CEO of US biomed company Ovid Therapeutics, which is trying to find a drug treatment for autism. Levin has been chairman of the company for the past year, but because of his faith in it, he has decided to run it.
Date: Apr 16, 2015
Category: Health
Source: Google
Bristol-Myers Operating Chief to Become CEO in May -- 2nd Update
Mr. Cornelius, 71, will retire from the board as part of the leadership changes, Bristol said. Other architects ofBristol's transformation have previously left the company, including executives Elliott Sigal and Jeremy Levin.
In 2013, then-CEO Jeremy Levin said he wondered whether Teva's 74 facilities were too many, but he ran into problems with the board and was ousted. Vigodman, who replaced Levin, and other Teva officials say they are closing facilities and reviewing others. Teva is also trying to cut its $10 billion
Date: Oct 31, 2014
Category: Business
Source: Google
NuPathe nixes Endo's buyout offer to hook up with Teva
months earlier than anticipated. At the J.P. Morgan Healthcare Conference last week, CFO Eyal Desheh promised a spate of M&A, and quickly. Like Endo, Teva is cutting jobs and costs to retrench; it's awaiting the advent of new CEO Erez Vigodman, who'll take over for ex-chief Jeremy Levin on Feb. 11.
Date: Jan 21, 2014
Category: Business
Source: Google
Teva Gains as CFO Vows to Cut Costs While Changes Accelerate (1)
receipts of Petach Tikva, Israel-basedTeva increased 6.7 percent to $44.21 at the close in New York,the highest price since May 8, 2012. The receipts fell to a two-year low on Nov. 4 after Jeremy Levin, Tevas former chiefexecutive officer, resigned. Each receipt is equal to oneregular share.
Christian Smith, Patrick Humm, Melissa Allen, Connet Clark, Peter Rowe, Monica Demaras, Michael Gary, Bradley Baker, Theresa Bass, Joseph Johnson, Molly Arnold